Phillip Gross's Net Worth

$2.26 Billion

Who is Phillip Gross?

Phillip Gross has an estimated net worth of $2.26 Billion. This is based on reported shares across multiple companies, which include ORBCOMM Inc., HeartWare International, Inc., Royalty Pharma plc, Celanese Corp, SELECT COMFORT CORP, MULESOFT, INC, GCM Grosvenor Inc., Solaris Oilfield Infrastructure, Inc., HUBBELL INC, Protagonist Therapeutics, Inc, Mandalay Digital Group, Inc., PUMA BIOTECHNOLOGY, INC., Calithera Biosciences, Inc., CONCERT PHARMACEUTICALS, INC., Advaxis, Inc., Nexvet Biopharma plc, AMCI Acquisition Corp., AMAG PHARMACEUTICALS INC., East Resources Acquisition Co, PACIFIC SUNWEAR OF CALIFORNIA INC, Vitae Pharmaceuticals, Inc, SMART BALANCE, INC., FIVE PRIME THERAPEUTICS INC, CARDIOME PHARMA CORP, Targanta Therapeutics Corp., GENEVA ACQUISITION CORP, and ABEONA THERAPEUTICS INC..

SEC CIK

Phillip Gross's CIK is 0001403413

Past Insider Trading and Trends

2015 was Phillip Gross's most active year for acquiring shares with 26 total transactions. Phillip Gross's most active month to acquire stocks was the month of July. 2017 was Phillip Gross's most active year for disposing of shares, totalling 38 transactions. Phillip Gross's most active month to dispose stocks was the month of March. 2020 saw Phillip Gross paying a total of $84,000,000.00 for 46,015,330 shares, this is the most they've acquired in one year. In 2020 Phillip Gross cashed out on 13,056,561 shares for a total of $333,391,124.70, their largest year based on trade value.